Thank you for visiting us. We are currently updating our shopping cart and regret to advise that it will be unavailable until September 1, 2014. We apologise for any inconvenience and look forward to serving you again.

Wiley
Wiley.com
Print this page Share

Advanced Therapy for Hepatitis C

ISBN: 978-1-4051-8745-9
232 pages
December 2011, Wiley-Blackwell
Advanced Therapy for Hepatitis C (140518745X) cover image
According to the WHO, 170 million people, or 3% of the world's population, are infected with Hepatitis C and at risk of developing liver cirrhosis and/or liver cancer.   3-4 million people each year are newly diagnosed carriers of the virus.

Advanced Therapy for Hepatitis C Infection provides you with expert guidance from the world’s leading hepatologists on the very latest treatment options for patients with the HCV virus.  Focusing mainly on the efficacy and clinical use of antiviral therapies, key topics include:

  • Treatment of recurrent hepatitis C following liver transplantation
  • Antivirals in Cirrhosis and Portal Hypertension
  • HIV and Hepatitis C co-infection
  • Cytopenias: how they limit therapy and potential correction
  • The problem of insulin resistance and its effect on therapy
  • Antivirals in Acute Hepatitis C

In addition, it fully covers the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs.  Finally, a chapter on New Horizons:  Interleukin 28 and direct-acting antiviral therapy for HCV, offers you a glimpse into the future possibilities for HCV therapy.   

Edited by a team of outstanding international reputation, Advanced Therapy for Hepatitis C Infection is an essential tool for all hepatologists and gastroenterologists involved in the management of patients with Hepatitis C.

See More
Contributors, vii

Preface, xi

Section I Foundations for Understanding Antiviral Therapies in HCV

1 HCV Replication, 3
Michael R. Beard

2 Hepatitis C Virus Genotypes, 12
Scott A. Read and Mark W. Douglas

3 Immune Responses to HCV: Implications for Therapy, 17
David G. Bowen

4 Mechanisms of Action of Antiviral Drugs: The Interferons, 25
Edmund Tse and Michael R. Beard

5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs, 36
Fred Poordad and Grace M. Chee

6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors, 43
Lotte Coelmont, Leen Delang, Mathy Froeyen, Piet Herdewijn and Johan Neyts

7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors, 53
Laurent Chatel-Chaix, Martin Baril and Daniel Lamarre

8 Measuring Antiviral Responses, 60
Jean-Michel Pawlotsky and Stephane Chevaliez

Section II Efficacy and Clinical Use of Antiviral Therapies

9 Genotype 1: Standard Treatment, 67
Rebekah G. Gross and Ira M. Jacobson

10 Individually Tailored Treatment Strategies in Treatment-na¨ive Chronic Hepatitis C Genotype 1 Patients, 74
Johannes Wiegand and Thomas Berg

11 Genotype 1 Relapsers and Non-responders, 84
Salvatore Petta and Antonio Crax`i

12 Standard Therapy for Genotypes 2/3, 90
Kenneth Yan and Amany Zekry

13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3, 97
Alessandra Mangia, Leonardo Mottola and Angelo Andriulli

14 Genotypes 2 and 3 Relapse and Non-response, 104
Stella Mart´inez, Jose Maria Sanchez-Tapias and Xavier Forns

15 Hepatitis C Genotype 4 Therapy: Progress and Challenges, 113
Sanaa M. Kamal

16 Antivirals in Acute Hepatitis C, 127
Heiner Wedemeyer

17 Antivirals in Cirrhosis and Portal Hypertension, 132
Diarmuid S. Manning and Nezam H. Afdhal

18 Treatment of Recurrent Hepatitis C Following Liver Transplantation, 140
Ed Gane

19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations, 150
Benjamin Terrier and Patrice Cacoub

20 Cytopenias: How they Limit Therapy and Potential Correction, 160
Mitchell L. Shiffman

21 The Problem of Insulin Resistance and its Effect on Therapy, 169
Venessa Pattullo and Jacob George

22 HIV and Hepatitis C Co-infection, 177
Gail V. Matthews and Gregory J. Dore

23 HCV and Racial Differences, 185
Andrew J. Muir

24 HCV and the Pediatric Population, 190
Kathleen B. Schwarz

25 New Horizons: IL28, Direct-acting Antiviral Therapy for HCV, 196
Alexander J. Thompson, John G. McHutchison and Geoffrey W. McCaughan

Index, 215

See More
Professor Geoff McCaughan is Director of the AW Morrow Liver Centre and Physician in Charge at the Australian National Liver Transplant Unit.

John McHutchison is a professor of medicine at Duke University Medical Center, and since 2002, Director of the DCRI’s Gastroenterology and Hepatology Research division.

See More

“I think it is an invaluable respository of knowledge for anyone embarking on a career caring for patients with viral hepatitis. This book summarises the hard won clinical knowledge of the past 20 years.”  (The Irish Medical Journal, 1 January 2013)

See More
Buy Both and Save 25%!
+

Advanced Therapy for Hepatitis C (US $124.95)

-and- Clinical Dilemmas in Primary Liver Cancer (US $89.95)

Total List Price: US $214.90
Discounted Price: US $161.17 (Save: US $53.73)

Buy Both
Cannot be combined with any other offers. Learn more.

Related Titles

Back to Top